세계의 혈액제제 시장 보고서 : 제품별, 항혈전 및 항응고제 유형별, 항혈전 및 항응고제 용도별, 지역별(2024-2032년)

The global blood preparation market size reached US$ 44.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 64.9 Billion by 2032, exhibiting a growth rate (CAGR) of 4.2% during 2024-2032.

Blood donation is a lifesaving procedure wherein one unit of blood is taken from the donor. This blood consists of a mixture of cellular elements, colloids, and crystalloids, which need to be separated for being used in patients. As a result, the blood preparation method is widely adopted to separate one-unit whole blood into different components using refrigerated centrifuge equipment. These components generally include cryoprecipitate, platelet concentrate, fresh frozen plasma, and packed red blood cell (PRBC) concentrate. The blood preparation method also maximizes the utility of each blood component for a different applications.

Blood Preparation Market Trends:

Due to the surging cases of coronavirus disease (COVID-19) and the lack of effective treatment, several hospitals are relying on convalescent plasma as a promising treatment for patients with critical conditions. This represents one of the key factors positively influencing the need for blood preparation methods to separate plasma from healthy blood donations. Apart from this, the growing prevalence of chronic disorders, such as anemia, sickle cell disease, hemophilia, and cancer, is catalyzing the demand for blood transfusion. This, in confluence with the rising number of blood donors on account of awareness campaigns conducted by governmental and non-governmental organizations (NGOs) worldwide, is contributing to the market growth. In line with this, a significant rise in the number of surgical procedures is also bolstering the growth of the market. Moreover, several healthcare institutions are focusing on employing advanced digital technologies for the speedy separation of blood components. They are also utilizing radio frequency identification (RFID) technology for maintaining blood inventory records, which is anticipated to expand the application of blood preparation methods in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global blood preparation market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, antithrombotic and anticoagulants type, and antithrombotic and anticoagulants application.

Breakup by Product:

Whole Blood

Red Cells

Granulocytes

Plasma

Platelets

Blood Components

Whole Blood Components

Packed Red Cells

Leukocyte Reduced Red Blood Cells

Frozen Plasma

Platelet Concentrate

Cryoprecipitate

Blood Derivatives

Breakup by Antithrombotic and Anticoagulants Type:

Platelet Aggregation Inhibitors

Glycoprotein Inhibitors

COX Inhibitors

ADP Antagonists

Others

Fibrinolytics

Tissue Plasminogen Activator (TPA)

Streptokinase

Urokinase

Anticoagulants

Heparins

Vitamin K Antagonists

Direct Thrombin Inhibitors

Direct Factor Xa Inhibitors

Breakup by Antithrombotic and Anticoagulants Application:

Thrombocytosis

Pulmonary Embolism

Renal Impairment

Angina Blood Vessel Complications

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Baxter International Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, GlaxoSmithKline PLC, Johnson & Johnson Services Inc., LEO Pharma A/S, Pfizer Inc., Portola Pharmaceuticals Inc. (Alexion Pharmaceuticals Inc.) and Sanofi S.A.

Key Questions Answered in This Report

• 1. What was the size of the global blood preparation market in 2023?
• 2. What is the expected growth rate of the global blood preparation market during 2024-2032?
• 3. What are the key factors driving the global blood preparation market?
• 4. What has been the impact of COVID-19 on the global blood preparation market?
• 5. What is the breakup of the global blood preparation market based on the product?
• 6. What is the breakup of the global blood preparation market based on the antithrombotic and anticoagulants type?
• 7. What is the breakup of the global blood preparation market based on the antithrombotic and anticoagulants application?
• 8. What are the key regions in the global blood preparation market?
• 9. Who are the key players/companies in the global blood preparation market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Blood Preparation Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Whole Blood
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Red Cells
    • 6.1.2.2 Granulocytes
    • 6.1.2.3 Plasma
    • 6.1.2.4 Platelets
  • 6.1.3 Market Forecast
• 6.2 Blood Components
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Whole Blood Components
    • 6.2.2.2 Packed Red Cells
    • 6.2.2.3 Leukocyte Reduced Red Blood Cells
    • 6.2.2.4 Frozen Plasma
    • 6.2.2.5 Platelet Concentrate
    • 6.2.2.6 Cryoprecipitate
  • 6.2.3 Market Forecast
• 6.3 Blood Derivatives
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Antithrombotic and Anticoagulants Type

• 7.1 Platelet Aggregation Inhibitors
  • 7.1.1 Market Trends
  • 7.1.2 Key Segments
    • 7.1.2.1 Glycoprotein Inhibitors
    • 7.1.2.2 COX Inhibitors
    • 7.1.2.3 ADP Antagonists
    • 7.1.2.4 Others
  • 7.1.3 Market Forecast
• 7.2 Fibrinolytics
  • 7.2.1 Market Trends
  • 7.2.2 Key Segments
    • 7.2.2.1 Tissue Plasminogen Activator (TPA)
    • 7.2.2.2 Streptokinase
    • 7.2.2.3 Urokinase
  • 7.2.3 Market Forecast
• 7.3 Anticoagulants
  • 7.3.1 Market Trends
  • 7.3.2 Key Segments
    • 7.3.2.1 Heparins
    • 7.3.2.2 Vitamin K Antagonists
    • 7.3.2.3 Direct Thrombin Inhibitors
    • 7.3.2.4 Direct Factor Xa Inhibitors
  • 7.3.3 Market Forecast

8 Market Breakup by Antithrombotic and Anticoagulants Application

• 8.1 Thrombocytosis
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Pulmonary Embolism
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Renal Impairment
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Angina Blood Vessel Complications
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Others
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Baxter International Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Boehringer Ingelheim International GmbH
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 Bristol-Myers Squibb Company
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Daiichi Sankyo Company Limited
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 GlaxoSmithKline PLC
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Johnson & Johnson Services Inc.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
  • 14.3.7 LEO Pharma A/S
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 SWOT Analysis
  • 14.3.8 Pfizer Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Portola Pharmaceuticals Inc. (Alexion Pharmaceuticals Inc.)
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
  • 14.3.10 Sanofi S.A.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis